Crossmark

Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers

Crossref DOI link: https://doi.org/10.1007/s10637-021-01071-z

Published Online: 2021-01-27

Published Print: 2021-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhu, Yun-ting

Zhang, Yi-fan

Jiang, Jin-fang

Yang, Yong

Guo, Li-xia

Bao, Jing-jing

Zhong, Da-fang
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (No 81521005)

Strategic Priority Research Program of the Chinese Academy of Sciences (No XDA12050306)
License Information

Text and Data Mining valid from 2021-01-27

Version of Record valid from 2021-01-27
More Information

Article History

Received: 23 August 2020

Accepted: 19 January 2021

First Online: 27 January 2021

Declarations

:

: Jing-jing Bao was the employee of Shanghai Allist Pharmaceuticals Co., Ltd. at the time the study was conducted. The remaining authors have declared no conflicts of interest.

: The study protocol was approved by the Independent Ethics Committee of the hospital, and was carried out in full compliance with the principles of the ‘Declaration of Helsinki’ (current revision) and ‘Good Clinical Practice’ guideline. Written informed consent was obtained from all participants before the start of treatment or any study-related procedures.

: All authors have approved the manuscript and agree with its publication.

: This is a research involving human participants.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below